[go: up one dir, main page]

WO1998042746A3 - Synthetic saposin c-derived neurotrophic peptides - Google Patents

Synthetic saposin c-derived neurotrophic peptides Download PDF

Info

Publication number
WO1998042746A3
WO1998042746A3 PCT/US1998/005503 US9805503W WO9842746A3 WO 1998042746 A3 WO1998042746 A3 WO 1998042746A3 US 9805503 W US9805503 W US 9805503W WO 9842746 A3 WO9842746 A3 WO 9842746A3
Authority
WO
WIPO (PCT)
Prior art keywords
saposin
derived neurotrophic
neurotrophic peptides
promote
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005503
Other languages
French (fr)
Other versions
WO1998042746A9 (en
WO1998042746A2 (en
WO1998042746B1 (en
Inventor
John S O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Neurosciences Corp
Original Assignee
Myelos Neurosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Neurosciences Corp filed Critical Myelos Neurosciences Corp
Priority to CA002284105A priority Critical patent/CA2284105A1/en
Priority to EP98926027A priority patent/EP0971956A2/en
Priority to AU77956/98A priority patent/AU7795698A/en
Publication of WO1998042746A2 publication Critical patent/WO1998042746A2/en
Publication of WO1998042746A3 publication Critical patent/WO1998042746A3/en
Publication of WO1998042746B1 publication Critical patent/WO1998042746B1/en
Publication of WO1998042746A9 publication Critical patent/WO1998042746A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Non-naturally occurring synthetic peptide analogs derived from the active neurotrophic region of saposing C. The saposin C-derived peptides induce neurite outgrowth in vitro, promote myelination, promote neuroprotection and prevent programmed cell death and have an analgesic effect. They are useful in the treatment of central and peripheral nervous system disorders and pain management.
PCT/US1998/005503 1997-03-24 1998-03-20 Synthetic saposin c-derived neurotrophic peptides Ceased WO1998042746A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002284105A CA2284105A1 (en) 1997-03-24 1998-03-20 Synthetic saposin c-derived neurotrophic peptides
EP98926027A EP0971956A2 (en) 1997-03-24 1998-03-20 Synthetic saposin c-derived neurotrophic peptides
AU77956/98A AU7795698A (en) 1997-03-24 1998-03-20 Synthetic saposin c-derived neurotrophic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82342597A 1997-03-24 1997-03-24
US08/823,425 1997-03-24

Publications (4)

Publication Number Publication Date
WO1998042746A2 WO1998042746A2 (en) 1998-10-01
WO1998042746A3 true WO1998042746A3 (en) 1998-11-26
WO1998042746B1 WO1998042746B1 (en) 1999-02-11
WO1998042746A9 WO1998042746A9 (en) 1999-03-11

Family

ID=25238739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005503 Ceased WO1998042746A2 (en) 1997-03-24 1998-03-20 Synthetic saposin c-derived neurotrophic peptides

Country Status (4)

Country Link
EP (1) EP0971956A2 (en)
AU (1) AU7795698A (en)
CA (1) CA2284105A1 (en)
WO (1) WO1998042746A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHODS FOR RELIEVING NEUROPATHIC PAIN
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
KR100973641B1 (en) * 2008-05-09 2010-08-02 성균관대학교산학협력단 Novel peptides increase protein expression of WNDF in hippocampal neurons, hippocampal tissue, and cerebral cortical tissue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003821A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Prosaposin and cytokine-derived peptides as therapeutic agents
WO1997032895A1 (en) * 1996-03-05 1997-09-12 Regents Of The University Of California Methods of alleviating neuropathic pain using prosaposin-derived peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003821A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Prosaposin and cytokine-derived peptides as therapeutic agents
WO1997032895A1 (en) * 1996-03-05 1997-09-12 Regents Of The University Of California Methods of alleviating neuropathic pain using prosaposin-derived peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOTANI E.A.: "A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo", J.NEUROSCIENCE, vol. 66, no. 5, 1996, pages 2197 - 2200, XP002077621 *
O'BRIEN E.A.: "Identification of the neurotrophc factor sequence of prosaposin", FASEB J., vol. 9, May 1995 (1995-05-01), pages 681 - 685, XP002077620 *
QI E.A.: "Functional organization of saponin C", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 12, 22 March 1996 (1996-03-22), MD US, pages 6874 - 6880, XP002077619 *
WEILER S ET AL: "SYNTHESIS AND CHARACTERIZATION OF A BIOACTIVE 82-RESIDUE SPHINGOLIPID ACTIVATOR PROTEIN, SAPOSIN C", JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 4, no. 3, 1993, pages 161 - 172, XP000651540 *

Also Published As

Publication number Publication date
EP0971956A2 (en) 2000-01-19
CA2284105A1 (en) 1998-10-01
WO1998042746A2 (en) 1998-10-01
AU7795698A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
CA2168029A1 (en) Prosaposin and cytokine-derived peptides as therapeutic agents
EP2347760A3 (en) Use of follistatin for the manufacture of a medicament for the treatment of a non-degenerative nervous system disorder
AU2192097A (en) System for individual dosage medication distribution
ATE212359T1 (en) NEUROTROPHIC PEPTIDES OF THE ACTIVITY-DEPENDENT NEUROTROPHIC FACTOR
AU5981098A (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
WO2000063246A3 (en) Compounds and methods for modulating beta-catenin mediated gene expression
TR199901734T2 (en) N�rotrofinlerin ar�t�lmas�.
WO2000075173A3 (en) Peptide fragments of colostrinin
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
DE69632967D1 (en) PREVENTION OF GRASS REPELLATION IN TRANSPLANTS AND FOR THE PRODUCTION OF UNIVERSAL GENE THERAPY IN THE CELL, USING LYMPHOYCYTE ACTIVATION GENE-3 (LAG-3)
WO1998042746A3 (en) Synthetic saposin c-derived neurotrophic peptides
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
CA2259152A1 (en) Adenovirus e4 proteins for inducing cell death
IL107674A0 (en) Multifunctional neurotrophic factors
WO1999029640A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor
IL132310A0 (en) Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
ATE356145T1 (en) POLYPEPTIDES FOR REGENERATING THE NERVOUS SYSTEM
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
EP0917535A4 (en) Neuroactive peptide
CA2100720A1 (en) Medicinal composition comprising tcf-ii
HK1044546A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
WO2003044040A3 (en) Alpha-fetoprotein peptides and uses thereof
WO2001034174A3 (en) Methods for administration of therapeutic agents on an antiangiogenic schedule
WO1998042746B1 (en) Synthetic saposin c-derived neurotrophic peptides
HU9600432D0 (en) Novel tripeptides useful in immune and cns therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2284105

Country of ref document: CA

Ref country code: CA

Ref document number: 2284105

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 77956/98

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 545829

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998926027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998926027

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998926027

Country of ref document: EP